These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 16236682)

  • 21. A randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia in patients with breast, lung, or gynecologic cancer.
    Schwartzberg LS; Yee LK; Senecal FM; Charu V; Tomita D; Wallace J; Rossi G
    Oncologist; 2004; 9(6):696-707. PubMed ID: 15561813
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dose and cost comparison of erythropoietic agents in the inpatient hospital setting.
    Vekeman F; McKenzie RS; Lefebvre P; Watson SH; Mody SH; Piech CT; Duh MS
    Am J Health Syst Pharm; 2007 Sep; 64(18):1943-9. PubMed ID: 17823106
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-minimization analysis of darbepoetin alfa versus epoetin alfa in the hospital setting.
    Kruep EJ; Basskin LE
    Am J Health Syst Pharm; 2005 Dec; 62(24):2597-603. PubMed ID: 16333057
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel approaches to anemia associated with cancer and chemotherapy.
    Kolesar JM
    Am J Health Syst Pharm; 2002 Aug; 59(15 Suppl 4):S8-11. PubMed ID: 12166035
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Use of erythropoietin-stimulating agents in breast cancer patients: a risk review.
    Crouch Z; DeSantis ER
    Am J Health Syst Pharm; 2009 Jul; 66(13):1180-5. PubMed ID: 19535656
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost of managing anemia with and without prophylactic epoetin alfa therapy in breast cancer patients receiving combination chemotherapy.
    Meadowcroft AM; Gilbert CJ; Maravich-May D; Hayward SL
    Am J Health Syst Pharm; 1998 Sep; 55(18):1898-902. PubMed ID: 9784769
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical and economic comparison of epoetin alfa and darbepoetin alfa.
    Morreale A; Plowman B; DeLattre M; Boggie D; Schaefer M
    Curr Med Res Opin; 2004 Mar; 20(3):381-95. PubMed ID: 15025847
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Benefits associated with an early hemoglobin response to epoetin alfa therapy in the treatment of chemotherapy-related anemia.
    Campos SM; Duh MS; Lefebvre P; Rosberg J
    J Natl Compr Canc Netw; 2005 Nov; 3(6):807-16. PubMed ID: 16316616
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Epoetins and [symbol: see text] darbepoetin alfa in malignant disease.
    Drug Ther Bull; 2004 Mar; 42(3):21-3. PubMed ID: 15038080
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Guidelines for using darbepoetin alfa in patients with chemotherapy-induced anemia.
    Bloomfield M; Jaresko G; Zarek J; Dozier N
    Pharmacotherapy; 2003 Dec; 23(12 Pt 2):110S-118S. PubMed ID: 14695000
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Epoetin alfa and darbepoetin alfa: effects on ventricular hypertrophy in patients with chronic kidney disease.
    Chen HH; Tarng DC; Lee KF; Wu CY; Chen YC
    J Nephrol; 2008; 21(4):543-9. PubMed ID: 18651544
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-utility analysis of survival with epoetin-alfa versus placebo in stage IV breast cancer.
    Martin SC; Gagnon DD; Zhang L; Bokemeyer C; Van Marwijk Kooy M; van Hout B
    Pharmacoeconomics; 2003; 21(16):1153-69. PubMed ID: 14594437
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of long-acting growth factors on practice dynamics and patient satisfaction.
    Beveridge RA; Rifkin RM; Moleski RJ; Milkovich G; Reitan JF; Paivanas TA; Jacobs RJ
    Pharmacotherapy; 2003 Dec; 23(12 Pt 2):101S-109S. PubMed ID: 14694999
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Overview of cancer-related anemia: focus on the potential role of darbepoetin alfa.
    Valley AW
    Pharmacotherapy; 2002 Sep; 22(9 Pt 2):150S-159S. PubMed ID: 12222585
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Outcomes of erythropoiesis-stimulating agents in cancer patients with chemotherapy-induced anemia.
    Pashos CL; Larholt K; Fraser KA; McKenzie RS; Senbetta M; Piech CT
    Support Care Cancer; 2012 Jan; 20(1):159-65. PubMed ID: 21359879
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effectiveness and safety of an induction therapy with epoetin alfa in anemic cancer patients receiving concomitant chemotherapy.
    Cortesi E; Mancuso A; De Pasquale Ceratti A; Pizzardi N; D'Auria G; Accettura C; Beccaglia P; Bertelletti D; De Marinis F
    Oncologist; 2004; 9(4):459-68. PubMed ID: 15266099
    [TBL] [Abstract][Full Text] [Related]  

  • 37. What are cancer patients willing to pay for prophylactic epoetin alfa? A cost-benefit analysis.
    Ortega A; Dranitsaris G; Puodziunas AL
    Cancer; 1998 Dec; 83(12):2588-96. PubMed ID: 9874467
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The importance of clinical variables in comparative analyses using propensity-score matching: the case of ESA costs for the treatment of chemotherapy-induced anaemia.
    Polsky D; Eremina D; Hess G; Hill J; Hulnick S; Roumm A; Whyte JL; Kallich J
    Pharmacoeconomics; 2009; 27(9):755-65. PubMed ID: 19757869
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A retrospective cohort study to assess the impact of therapeutic substitution of darbepoetin alfa for epoetin alfa in anemic patients with myelodysplastic syndrome.
    Patton JF; Sullivan T; Mun Y; Reeves T; Rossi G; Wallace JF
    J Support Oncol; 2005; 3(6):419-26. PubMed ID: 16350429
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New oversight put in place for physicians giving anemia drugs to patients with cancer.
    Mitka M
    JAMA; 2010 Apr; 303(14):1355-6. PubMed ID: 20388885
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.